Alkeon Capital Management LLC Buys 120,199 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Alkeon Capital Management LLC has increased its holdings in BioCryst Pharmaceuticals by 1.7%, owning approximately 3.45% of the company, valued at around $54 million as of its latest SEC filing.
• BioCryst Pharmaceuticals reported a quarterly earnings surprise, with $0.15 EPS compared to an expectation of $0.03, and a significant 49.5% year-over-year revenue growth to $163.35 million.
• Multiple brokerage firms, including JPMorgan and Wedbush, have raised their target prices for BioCryst Pharmaceuticals, indicating a generally positive outlook with a consensus rating of "Moderate Buy" and a target price of $16.70.

Alkeon Capital Management LLC boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 1.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,214,021 shares of the biotechnology company's stock after acquiring an additional 120,199 shares during the quarter. Alkeon Capital Management LLC owned about 3.45% of BioCryst Pharmaceuticals worth $54,105,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Headlands Technologies LLC acquired a new position in BioCryst Pharmaceuticals during the 1st quarter worth $32,000. GF Fund Management CO. LTD. acquired a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at approximately $33,000. GAMMA Investing LLC increased its stake in BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 5,449 shares during the last quarter. New Age Alpha Advisors LLC bought a new position in shares of BioCryst Pharmaceuticals in the 1st quarter worth about $62,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter worth about $79,000. 85.88% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Bank of America increased their price objective on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Tuesday, July 1st. Needham & Company LLC restated a "buy" rating and issued a $17.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, August 4th. Wedbush lifted their price target on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a report on Monday, June 30th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. Finally, Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 26th. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, BioCryst Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $16.70.

Insider Transactions at BioCryst Pharmaceuticals

In related news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the sale, the director owned 65,352 shares of the company's stock, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.10% of the company's stock.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX remained flat at $8.27 during mid-day trading on Friday. 3,086,063 shares of the stock traded hands, compared to its average volume of 2,144,290. The stock has a market capitalization of $1.74 billion, a PE ratio of -45.94, a price-to-earnings-growth ratio of 1.88 and a beta of 1.13. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.01 and a twelve month high of $11.31. The business has a 50 day simple moving average of $8.52 and a 200-day simple moving average of $8.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. During the same period last year, the firm earned ($0.06) EPS. BioCryst Pharmaceuticals's quarterly revenue was up 49.5% on a year-over-year basis. As a group, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.